Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones

NCT: NCT07272720 · RECRUITING

NCT IDNCT07272720
StatusRECRUITING
Start Date2025-12-11
Completion2028-10
SponsorStorz Medical AG (INDUSTRY)
First posted
Last updated

Brief Summary

Extracorporeal shockwave lithotripsy (ESWL) is a non-invasive standard treatment for kidney stones. This study will be conducted to evaluate the effectiveness of ESWL using MODULITH® SLX-F2 with stone tracking, compared to MODULITH® SLX-F2 without stone tracking, in adult patients with kidney stones, as measured by stone-free status.

Frequently Asked Questions

What is PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones?

PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones is a clinical trial registered under NCT07272720. Current status: RECRUITING.

What is the status of NCT07272720?

The current status of NCT07272720 (PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones) is: RECRUITING.

When did PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones start?

PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones started on 2025-12-11.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.